C-reactive protein: A differential biomarker for major depressive disorder and bipolar II disorder
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Objectives We aimed to examine whether the C-reactive protein (CRP) level could be used to differentiate between major depressive disorder (MDD) and bipolar II disorder (BD II). Methods Ninety-six healthy controls, 88 BD II and 72 MDD drug-naïve patients in their major depressive episodes were enrolled. The fasting plasma level of high-sensitivity CRP was assessed at baseline and after treatment. Results The BD II patients presented significantly higher 17-item Hamilton Depression Rating Scale (HDRS) scores and CRP levels at baseline when adjustment for age, gender, and body mass index (P < 0.001 and P < 0.001, respectively). After treatment the CRP levels remained significantly different (P < 0.001), although the HDRS score was not significantly different between the BD II and MDD patients. A receiver-operating characteristic analysis showed that a baseline CRP level of 621.6 ng/mL could discriminate between BD II and MDD, with an area under the curve of 0.816 and a sensitivity and specificity of 0.699 and 0.882, respectively. Furthermore, the baseline CRP level greater than 621.6 ng/ml had 28.2 higher odds of a diagnosis of BD II (P < 0.001, 95% confidence interval: 10.96-72.35). Conclusions The level of CRP plays a role of biomarker to differentiate between MDD and BD II depression in both their depressed and euthymic state.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study proposed CRP as a biomarker to differentiate MDD and BD type 2 (BD-II), by recruiting 88 BD-II, 72 drug-naïve MDD and 96 healthy controls [79]. The authors found that a baseline CRP level of 621.6 ng/mL could discriminate between MDD and BD-II in both depressed and euthymic states [79].”
From C-Reactive protein as a biomarker for major depressive disorder? (2022) · cites this paper as [79]
Citations
Cites
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401 · cited 1×
“…Department of Psychiatry, National Cheng Kung University Hospital, 138 Sheng Li Road, North Dist., Tainan 70403, Taiwan 2016 Informa UK Limited, trading as Taylor & Francis Group cardiovascular diseases and metabolic disturbances (Pearson et al. 2003; Nordestgaard and Zacho 2009; Wei et al. 2014).”
BackgroundROCR: visualizing classifier performance in R
Sing, T., Sander, O., Beerenwinkel, N., & Lengauer, T. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti623 · Cited by 3,200 · cited 1×
“Furthermore, the odds ratios were determined for all the cut-off points corresponding to the baseline CRP levels using R 2.13.1 software in the ROCR package (Sing et al. 2005).”
MethodInfluentialHodes, G. E., Pfau, M. L., Leboeuf, M., Golden, S. A., Christoffel, D. J., Bregman, D., Rebusi, N., Heshmati, M., Aleyasin, H., Warren, B. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415191111 · Cited by 692 · cited 1×
“Moreover, the higher level of CRP could be considered as evidence that link peripheral immune dysfunction to BD susceptibility in mood disorder patients (Anand et al. 2009; Hodes et al. 2014; Dargel et al. 2015; Harrison et al. 2015).”
BackgroundHantouche, E. G., Akiskal, H. S., Lancrenon, S., Allilaire, J.-F., Sechter, D., Azorin, J.-M., Bourgeois, M., Fraud, J.-P., & Châtenet-Duchêne, L. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00112-8 · Cited by 435 · cited 1×
“A systematic search found that 40% of major depressive episodes could be classified as BD II; however, only half of these were recognised by clinicians (Hantouche et al. 1998).”
BackgroundLeverich, G. S., Altshuler, L. L., Frye, M. A., Suppes, T., McElroy, S. L., Keck, P. E., Kupka, R. W., Denicoff, K. D., Nolen, W. A., Grunze, H., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.232 · Cited by 419 · cited 1×
“Moreover, compared with SSRI treatment, tricyclic antidepressant and SNRI treatment have been found to be related to a risk of induction of mood switch (Leverich et al. 2006; Amsterdam and Shults 2010).”
ResultCan bipolar disorder be viewed as a multi-system inflammatory disease?
Leboyer, M., Soreca, I., Scott, J., Frye, M., Henry, C., Tamouza, R., & Kupfer, D. J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.12.049 · Cited by 417 · cited 1×
“It has been proposed that the pathophysiology of BD may not be limited to neurotransmitter abnormalities, but may reflect multifunctional system dysfunction, including the immune system (Leboyer et al. 2012; Rosenblat and McIntyre 2015).”
BackgroundAngst, J. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.87 · Cited by 417 · cited 1×
“At present, few phenotypes have been confirmed to differentiate BD II depression from unipolar depression (Angst et al. 2011).”
BackgroundAnand, A., Li, Y., Wang, Y., Lowe, M. J., & Dzemidzic, M. (2009) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2008.03.012 · Cited by 353 · cited 1×
“Moreover, the higher level of CRP could be considered as evidence that link peripheral immune dysfunction to BD susceptibility in mood disorder patients (Anand et al. 2009; Hodes et al. 2014; Dargel et al. 2015; Harrison et al. 2015).”
BackgroundVogelzangs, N., Duivis, H. E., Beekman, A. T. F., Kluft, C., Neuteboom, J., Hoogendijk, W., Smit, J. H., de Jonge, P., & Penninx, B. W. J. H. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.8 · Cited by 323 · cited 1×
“Adjunct medications with antiinflammatory activity might help to improve the treatment outcome and also reduce co-morbidity in BD II depression (Vogelzangs et al. 2012).”
BackgroundMansur, R. B., Brietzke, E., & McIntyre, R. S. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.017 · Cited by 322 · cited 1×
“Because patients with elevated inflammation are more likely to be obese and meet the criteria for metabolic syndrome, the difference in the CRP level might also be linked to the differing prevalence of metabolic syndrome among MDD, BD II and BD I patients (Mansur et al. 2015).”
Background
Cited by
Neuroinflammation in Bipolar Depression
Benedetti, F., Aggio, V., Pratesi, M. L., Greco, G., & Furlan, R. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00071 · Cited by 274
Fernandes, B. S., Steiner, J., Molendijk, M. L., Dodd, S., Nardin, P., Gonçalves, C.-A., Jacka, F., Köhler, C. A., Karmakar, C., Carvalho, A. F., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30370-4 · Cited by 247
Menzel, A., Samouda, H., Dohet, F., Loap, S., Ellulu, M. S., & Bohn, T. (2021) · Antioxidants · doi:10.3390/antiox10030414 · Cited by 217
“Recent work has further indicated that mental disorders, including bipolar disorder and chronic depression, are often linked with abnormalities in the immune system, including CRP [416].”
BackgroundSolmi, M., Suresh Sharma, M., Osimo, E. F., Fornaro, M., Bortolato, B., Croatto, G., Miola, A., Vieta, E., Pariante, C. M., Smith, L., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.07.014 · Cited by 196
C-Reactive protein as a biomarker for major depressive disorder?
Orsolini, L., Pompili, S., Tempia Valenta, S., Salvi, V., & Volpe, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031616 · Cited by 171
“Moreover, CRP levels were strongly and positively associated with depression severity [81] Another study proposed CRP as a biomarker to differentiate MDD and BD type 2 (BD-II), by recruiting 88 BD-II, 72 drug-naïve MDD and 96 healthy controls [79].”
BackgroundInfluential
Metadata
- Authors
- Chang, H. H., Wang, T.-Y., Lee, I. H., Lee, S.-Y., Chen, K. C., Huang, S.-Y., Yang, Y. K., Lu, R.-B., & Chen, P. S.
- Affiliations
- National Cheng Kung University (TW)
- National Cheng Kung University Hospital (TW)
- Kaohsiung Veterans General Hospital (TW)
- Tri-Service General Hospital (TW)
- Corresponding author
- Chen, Po See
- ORCID
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2016-04-20
- Volume
- 18
- Issue
- 1
- Pages
- 63-70
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2281714211
- Cited by
- 61
- References
- 49
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 6 · 2023: 10 · 2022: 12 · 2021: 9 · 2020: 1 · 2019: 5 · 2018: 4 · 2017: 1 · 2016: 4
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The World Journal of Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Council
- National Cheng Kung University Hospital
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- C-reactive protein, major depressive disorder, bipolar II disorder, differential diagnosis, inflammatory markers, high-sensitivity CRP, depression severity, euthymic state, antidepressant response
- MeSH terms
- Adult, Bipolar Disorder, C-Reactive Protein, Major Depressive Disorder, Female, Humans, Male, Middle Aged, ROC Curve, Sensitivity and Specificity, Taiwan, Biomarkers, Logistic Models, Case-Control Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: C-reactive protein: A differential biomarker for major depressive disorder and bipolar II disorder. https://app.cochat.ai/papers/10.3109/15622975.2016.1155746
- The paper
- Chang, H. H., Wang, T.-Y., Lee, I. H., Lee, S.-Y., Chen, K. C., Huang, S.-Y., Yang, Y. K., Lu, R.-B., & Chen, P. S. (2017). C-reactive protein: A differential biomarker for major depressive disorder and bipolar II disorder. The World Journal of Biological Psychiatry. https://doi.org/10.3109/15622975.2016.1155746
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.